- Home
- SNES vs PMN Comparison
SNES vs PMN Comparison
Compare SNES & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- PMN
- Stock Information
- Founded
- SNES 2004
- PMN 2004
- Country
- SNES United States
- PMN Canada
- Employees
- SNES N/A
- PMN N/A
- Industry
- SNES Agricultural Chemicals
- PMN Pharmaceuticals and Biotechnology
- Sector
- SNES Industrials
- PMN Health Care
- Exchange
- SNES Nasdaq
- PMN Nasdaq
- Market Cap
- SNES 24.0M
- PMN 22.3M
- IPO Year
- SNES 2016
- PMN N/A
- Fundamental
- Price
- SNES $4.13
- PMN $0.55
- Analyst Decision
- SNES Strong Buy
- PMN Strong Buy
- Analyst Count
- SNES 1
- PMN 3
- Target Price
- SNES $10.00
- PMN $4.33
- AVG Volume (30 Days)
- SNES 138.8K
- PMN 768.1K
- Earning Date
- SNES 11-11-2025
- PMN 11-13-2025
- Dividend Yield
- SNES N/A
- PMN N/A
- EPS Growth
- SNES N/A
- PMN N/A
- EPS
- SNES N/A
- PMN N/A
- Revenue
- SNES $2,093,000.00
- PMN N/A
- Revenue This Year
- SNES $49.17
- PMN N/A
- Revenue Next Year
- SNES $89.89
- PMN N/A
- P/E Ratio
- SNES N/A
- PMN N/A
- Revenue Growth
- SNES 36.89
- PMN N/A
- 52 Week Low
- SNES $1.30
- PMN $0.38
- 52 Week High
- SNES $6.24
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- SNES 43.60
- PMN 60.68
- Support Level
- SNES $3.74
- PMN $0.39
- Resistance Level
- SNES $4.76
- PMN $0.45
- Average True Range (ATR)
- SNES 0.32
- PMN 0.04
- MACD
- SNES -0.07
- PMN 0.02
- Stochastic Oscillator
- SNES 35.14
- PMN 71.45
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.